Dogwood Therapeutics Inc (DWTX) Stock Price, Quote & News

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 620 8655

Website: dwtx.com

Address:

44 Milton Avenue, Alpharetta, United States

cashcow1 Jan. 27 at 2:38 AM

$DWTX it will be a uptrend from now.

1 · Reply

cashcow1 Jan. 27 at 2:36 AM

$DWTX bullish

0 · Reply

Drainomight Jan. 23 at 2:34 PM

$DWTX

0 · Reply

cashcow1 Jan. 22 at 10:02 PM

$DWTX to the moon.

0 · Reply

Drainomight Jan. 22 at 2:44 PM

$DWTX

0 · Reply

cashcow1 Jan. 22 at 1:49 AM

$DWTX why no comments on this thread with 7000 watchers? Let’s send this stock to the moon.

0 · Reply

cashcow1 Jan. 22 at 1:47 AM

$DWTX nice bounce

1 · Reply

Drainomight Jan. 21 at 2:25 PM

$DWTX

0 · Reply

cashcow1 Jan. 20 at 8:08 PM

$DWTX any hope?

1 · Reply

cashcow1 Jan. 17 at 7:08 PM

$DWTX RSI shows reversal.

0 · Reply

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Dec 22, 2025, 10:15 AM EST - 5 weeks ago

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Dec 2, 2025, 8:00 AM EST - 2 months ago

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Nov 11, 2025, 8:45 AM EST - 2 months ago

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Nov 6, 2025, 8:45 AM EST - 2 months ago

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:15 AM EDT - 3 months ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 14, 2025, 8:45 AM EDT - 3 months ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 7, 2025, 8:45 AM EDT - 4 months ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Sep 29, 2025, 12:17 PM EDT - 4 months ago

Dogwood Therapeutics, Inc. - Special Call

Sep 29, 2025, 7:15 AM EDT - 4 months ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 3, 2025, 9:15 AM EDT - 5 months ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 9:00 AM EDT - 5 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 1:08 PM EDT - 6 months ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 6, 2025, 9:15 AM EDT - 6 months ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jun 3, 2025, 9:15 AM EDT - 8 months ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

May 8, 2025, 9:00 AM EDT - 9 months ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 1, 2025, 8:30 AM EDT - 9 months ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 11, 2025, 9:15 AM EDT - 10 months ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 3, 2025, 9:00 AM EDT - 10 months ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Mar 31, 2025, 3:45 PM EDT - 10 months ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 18, 2025, 8:45 AM EDT - 11 months ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 13, 2025, 9:00 AM EDT - 11 months ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 23, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

May 22, 2024, 1:30 PM EDT - 1 year ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 1 year ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 1 year ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 11, 2024, 11:44 PM EDT - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:45 AM EDT - 1 year ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Mar 26, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Feb 29, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Jan 22, 2024, 9:00 AM EST - 2 years ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 2, 2024, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Nov 13, 2023, 11:21 AM EST - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Aug 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 10, 2023, 10:05 AM EDT - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 9, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Jul 17, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

May 25, 2023, 4:05 PM EDT - 2 years ago

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

cashcow1 Jan. 27 at 2:38 AM

$DWTX it will be a uptrend from now.

1 · Reply

cashcow1 Jan. 27 at 2:36 AM

$DWTX bullish

0 · Reply

Drainomight Jan. 23 at 2:34 PM

$DWTX

0 · Reply

cashcow1 Jan. 22 at 10:02 PM

$DWTX to the moon.

0 · Reply

Drainomight Jan. 22 at 2:44 PM

$DWTX

0 · Reply

cashcow1 Jan. 22 at 1:49 AM

$DWTX why no comments on this thread with 7000 watchers? Let’s send this stock to the moon.

0 · Reply

cashcow1 Jan. 22 at 1:47 AM

$DWTX nice bounce

1 · Reply

Drainomight Jan. 21 at 2:25 PM

$DWTX

0 · Reply

cashcow1 Jan. 20 at 8:08 PM

$DWTX any hope?

1 · Reply

cashcow1 Jan. 17 at 7:08 PM

$DWTX RSI shows reversal.

0 · Reply

cashcow1 Jan. 17 at 7:07 PM

$DWTX 7000 watchers here. Hope it bounces soon.

0 · Reply

DonCorleone77 Jan. 16 at 1:34 AM

$SLVM $JBHT $QXO $DWTX $DERM AFTER-HOURS MOVERS: Currently Higher: - Sylvamo (SLVM) up 2.0% after 2026 outlook Currently Lower After Earnings: - J.B. Hunt Transport (JBHT) down 4.2% - WaFd (WAFD) down 0.7% Currently Also Lower: - QXO (QXO) down 4.0% after Q4 pre-announcement, $750M stock offering - Dogwood Therapeutics (DWTX) down 2.1% after equity offering - Journey Medical (DERM) down 2.0% after equity offering

0 · Reply

cashcow1 Jan. 15 at 11:17 PM

$DWTX why it goes up in pre market and goes down during market time?

1 · Reply

Drugtrade Jan. 15 at 9:26 PM

$DWTX this is not pure trash, they have 2 product.. it can recover a lot in a few months, is great for swing trade if low cost avg and never chasing. I would be adding at these levels not selling

0 · Reply

Drainomight Jan. 15 at 1:04 AM

$DWTX not happy with the current price, but I’m still holding. Risk is already taken, and I’d rather wait for clarity on the pipeline than to sell at a loss.

2 · Reply

fantastex Jan. 13 at 12:35 PM

$DWTX offering at 2.85 fellas .... warrants will be exercisable upon shareholder approval...what? Lol This should go to 2.50.... but seems super manipulated. Anyone buying out this for pennies?

0 · Reply

fantastex Jan. 13 at 12:32 PM

$DWTX told ya

0 · Reply

Finanz Jan. 12 at 5:44 PM

$DWTX Ugly financing

0 · Reply

Stock_Catcher Jan. 12 at 1:31 PM

$DWTX Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

0 · Reply

Stock__Hunter Jan. 12 at 12:58 AM

$DWTX Ntot done falling, what ever happened it was already baked into chart

0 · Reply

fantastex Jan. 9 at 6:24 PM

$DWTX offering anytime After market or on monday at 2.50/3 dollars... They are low on cash. They cant survive . Dilution incoming

0 · Reply

Stoksgeek Jan. 9 at 6:02 PM

$DWTX dont buy this garbage

0 · Reply

Market Cap	6.83M
Revenue (ttm)	0.00
Net Income (ttm)	-12.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	71,515
Avg Vol	50,462
Day's Range	N/A - N/A
Shares Out	2.29M
Stochastic %K	92%
Beta	1.90
Analysts	Strong Sell
Price Target	$19.00